Eterna Therapeutics
ERNA
#9826
Rank
S$8.04 M
Marketcap
$1.49
Share price
4.67%
Change (1 day)
-7.43%
Change (1 year)

P/E ratio for Eterna Therapeutics (ERNA)

P/E ratio as of November 2024 (TTM): -0.1986

According to Eterna Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.198582. At the end of 2021 the company had a P/E ratio of -1.50.

P/E ratio history for Eterna Therapeutics from 2021 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2021-1.50

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
6.77-3,506.97%๐Ÿ‡บ๐Ÿ‡ธ USA
-12.5 6,194.63%๐Ÿ‡บ๐Ÿ‡ธ USA
6.89-3,569.91%๐Ÿ‡บ๐Ÿ‡ธ USA
16.1-8,226.16%๐Ÿ‡ซ๐Ÿ‡ท France
48.4-24,463.84%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡ฆ๐Ÿ‡บ Australia
-8.56 4,208.04%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.